The human papillomavirus (HPV) seems to be involved in the pathogenesis of approximately 15% of human malignancies. However, in the past, the involvement of HPV infection in the development of prostate cancer has been controversial. Previously, highly variable frequencies ranging between 2% and 53% have been reported for the detectability of HPV 16 DNA in tissue obtained from benign prostatic hyperplasia (BPH) and prostate cancer specimens. The viral E6 protein expressed by HPV type 16 seems to be of special interest due to its ability to inactivate the physiological function of the p53 protein, the product of the p53 tumour suppressor gene. As former studies were based on qualitative PCR-based analytical approaches, the present investigations aimed at the comparative quanti®cation of the HPV 16 DNA content in prostate cancer and BPH.
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Method
For PCR-based quanti®cation of HPV 16 DNA, a homologous internal competitor sequence with an exchanged restriction site, utilising a plasmid encoded sequence of the viral E6 protein and site directed mutagenesis, was prepared. DNA was extracted from 47 fresh frozen prostate cancer samples obtained from patients undergoing radical prostatectomy for the treatment of clinically localised adenocarcinoma of the prostate, as well as from 47 patients treated for BPH. Following extraction, the DNA samples were subjected to analysis by a single-tube quantitative competitive PCR. Each step of ampli®cation was carried out 3-fold.
Results
Using single-tube quantitative competitive PCR, a subgroup of prostate tumours (10 of 47; 21%) was detected as having signi®cantly higher copy numbers of HPV 16-E6 sequences when compared to the control tissue (1 of 37; 3%), using a cut-off value of 300 copy numbers per 12.500 diploid cells (two-sided Fisher's exact test, P 0.02).
Conclusion
These results indicate that the oncogenic HPV 16 might contribute to the development of a subset of prostate cancers.
